The share buy-back programme is being launched within the authority granted by the shareholders at the Annual General Meeting on
The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the
The Company has retained Danske Bank A/S (“Danske Bank”) to act as manager of the share buyback programme and purchase shares on behalf of
The
- The programme will commence on
24 February 2020 and is expected to end by24 August 2020 . - The volume of trading in own shares will be limited to a maximum total market value of
DKK 500 million . - The maximum number of shares to be purchased in the company per daily market session will be the equivalent to 25% of the average volume of shares in the Company traded on
Nasdaq Copenhagen A/S during the preceding 20 business days. - During the life of the share buyback programme no shares will be purchased at a price exceeding the higher of the following two prices:
i) the price of the last independent trade on
ii) the highest current independent bid on
Details of transactions executed under the share buyback programme will be disclosed to the market in accordance with the Safe Harbour Regulation and will be publicly disclosed on the company’s website at least once every seventh trading day.
Prior to the launch of the share buyback programme
Executive Vice President, CFO
For more information, please contact:
Investors and analysts
Executive Vice President, CFO
Tel. +45 4911 1111
Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 / 4911 3376
E-mail dkebj@coloplast.com
Senior Manager, Investor Relations
Tel. +45 4911 1800 / 4911 1786
E-mail dkraso@coloplast.com
Press and the media
Lina Danstrup
Senior Media Relations Manager, Corporate Communications
Tel. +45 4911 2607
E-mail dklina@coloplast.com
Website
www.coloplast.com
Address
Holtedam 1
DK-3050 Humlebæk
Business reg. (CVR) no. 69749917
This announcement is available in a Danish and an English language version. In the event of discrepancies, the Danish version shall prevail.
The
Our business includes Ostomy Care, Interventional Urology, Continence Care and Wound and
Attachment
- 02_2020 Share buyback programme
© OMX, source